China Heparin Industry Report, 2010-2011
  • Sep./2011
  • Hard Copy
  • USD $1,900
  • Pages:71
  • Single User License
    (PDF Unprintable)       
  • USD $1,800
  • Code: HM006
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,700
  • Hard Copy + Single User License
  • USD $2,100
      
With richness in heparin materials and the quality of heparin API getting accredited by the international community, China has become one of the largest heparin API producers and exporters in the world. In 2010, there were 24 heparin API manufacturers with the heparin sodium API production license granted by SFDA in China, with the export volume of heparin API reaching 15.9 trillion units, with the market share making up 52.1% of the world's total in the corresponding period.

Export Volume and Proportion in the World of Heparin API in China, 2007-2010 (trillion units)
201109035.gif 
Source: ResearchInChina

Europe and America are the major export destinations of heparin API made in China. From January to July of 2011, heparin and heparinate made in China were exported to 44 countries. In terms of export volume, the top 5 export destinations were France, Germany, America, Austria and Italy, with the combined export volume standing at 83.7%.

It is required to obtain CEP certification of EU or FDA authentication of the US for companies to access into the European and American markets. Due to the stringent authentication criterion, many unqualified enterprises are forced to withdraw from the market. As of August, 2011, China had 5 CEP certified heparin API producers and 2 FDA certified ones. In particular, both Shenzhen Hepalink Pharmaceutical     and Changzhou Qianhong Bio-Pharma obtained the two certifications, an edge over the oppositions.

Although it is a large producer of heparin API, the production of downstream unfractionated heparin (UFH) sodium preparations and low-molecular-weight (LMW) heparin preparations in China is still in its infancy.

In the UFH preparation market, 26 Chinese companies have obtained the heparin sodium injection drug production licenses granted by SFDA. Due to the mounting pressure arising from the soaring price of heparin API, there are less than 10 companies that seem competitive in Chinese market, such as Tianjin Biochemical Pharmaceutical, Wanbang Biopharmaceuticals and Shanghai No.1 Chemical & Pharmaceutical, but all of them need to procure upstream raw material for production.

Restricted by the technology, the LMW heparin preparation market of China is dominated by foreign brands. In 2009, Chinese markets of LMW heparin sodium and LMW heparin calcium were dominated by France-based Sanofi’s Clexane and GSK’s Fraxiparine, topping the market with the respective share of 54.5% and 59.0%. However, the LMW heparin preparation products made by domestic companies become increasingly competitive with the enhanced strength in R&D and technology. For instance, the sales of Hebei Changshan Biochemical Pharmaceutical, a company producing LMW heparin calcium injection, rose 72.6% YoY to RMB51.612 million in 2010.
1. Profile of Heparin Industry
1.1 Definition & Classification
1.2 Industry Chain

2. International Operating Environment of Heparin Industry
2.1 Demand of Heparin Medicine
2.2 Distribution of Heparin Medicine Demand
2.3 Heparin API Demand
2.4 Overseas Competitors
2.5 Related Policies
2.6 Market Forecast

3. Current Development of China Heparin API Industry
3.1 Market Overview
3.2 Demand & Supply
3.3 Competition
3.4 Dynamics
3.5 Related Policies
3.6 Market Forecast

4. Current Development of China Heparin Preparation Industry
4.1 Overview of Antithrombotic Drugs
4.2 Market Overview
4.3 UFH Preparations
4.3.1 International Environment
4.3.2 Market Size
4.3.3 Competition
4.4 LMW Heparin Preparations
4.4.1 International Environment
4.4.2 Market Size
4.5 Demand & Supply
4.6 Competition
4.7 Dynamics & Patents
4.8 Market Forecast
5. Import & Export
5.1 Export
5.1.1 Export Volume
5.1.2 Export Destinations
5.2 Import
5.2.1 Import Destinations
5.2.2 Import Origins

6. Heparin Manufacturers in China
6.1 Shenzhen Hepalink Pharmaceutical
6.1.1 Profile
6.1.2 Operation
6.1.3 Dynamics
6.2 Changzhou Qianhong Bio-Pharma Co., Ltd
6.2.1 Profile
6.2.2 Operation
6.2.3 Dynamics
6.3 Tianjin Chase Sun Pharmaceutical
6.3.1 Profile
6.3.2 Operation
6.3.3 Dynamics
6.4 Hebei Changshan Biochemical Pharmaceutical
6.4.1 Profile
6.4.2 Operation
6.4.3 Dynamics
6.5 Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd
6.5.1 Profile
6.5.2 Operation
6.6 Yantai Dongcheng Biochemicals Co., Ltd
6.6.1 Profile
6.6.2 Operation
6.7 Wanbang Biopharmaceuticals
6.7.1 Profile
6.7.2 Operation
6.7.3 Dynamics
Application of Heparin Preparations
Heparin Industry Chain
Sales of Heparin Drugs Worldwide, 2003-2012E 
Distribution of Heparin Drug Consumption Worldwide, 2010
Market Size and Growth Rate of Heparin API Worldwide,2007-2013
Forecast of Global Heparin Drug Market Development 
Export Volume and The Global Proportion of Heparin API in China, 2007-2010
Number of Slaughtered Fattened Hogs (Head) and Year-end Number of Hogs (Head) of China, 2003-2010
Price Trend of Crude Sodium Heparin API in China, 2008-2010
Top ten Pharmaceutical Companies by Export Value of Heparin in China, Jan.-Sep.2010
Gross Margin of Major Heparin API Manufacturers in China, 2008-2010
Heparin Sodium API Supply in China and the World and China’s Share, 2011-2013
China Antithrombotic Drug Market Size, 2003-2012
Market Share of China's Major Varieties of Anti-thrombosis Drug in Hospital,2005-2009
Market Size of Heparin Drug in China,2007-2013
Chinese Market Share of Heparin Preparation Products, 2009
Market Size of Global UFH Preparations,2006-2012
Sales of UFH Preparations in China,2006-2012
Market Demand for Heparin Sodium Injection Solution in China, 2007-2012
Manufacturers of Heparin Sodium Injection Solution and Heparin Calcium Injection Solution in China
Operation of Major UFH Preparations Manufacturers in China,2008-2009
Performance Comparison between Low Molecular Weight Heparin Preparations and UFH Preparations
Market Size of Global Low Molecular Weight Heparin Preparations,2006-2012
Market Size of Low Molecular Weight Heparin Preparations in China,2006-2010
Proportion of Low-molecular Heparin Calcium and Low-molecular Heparin Sodium in Anticoagulant Medicines of China, 2005-2011
Manufacturers of Low-molecular Heparin Sodium Preparations and Low-molecular Heparin Calcium Preparations
Competition Pattern of China Low-Molecular-Weight Heparin Sodium Market, 2009
YoY Growth Rate for Sales of Main Competitive Enterprises of Low-molecular Weight Heparin Sodium in China, 2009
Competition Pattern of China Low-Molecular-Weight Heparin Calcium Market, 2009
YoY Growth Rate for Sales of Main Competitive Enterprises of Low-molecular Weight Heparin Calcium in China, 2009
Main Patents for LMW Heparin
China LMW Heparin Drug Market Size, 2010-2014 
Export of Key Western Medicines of China, Jan.-Jul. 2011
Export Value and Its Growth Rate of Heparin and Its Salts in China,2008-2011
China’s Export Volume and Price Trend of Heparin Products, 2008-2011
Overseas Market Distribution of Heparin Products in China, Jan.-Jul.2011
Main Chinese Exporting Enterprises of Heparin API and Their Percentages by Export Value, Jan.-Sep., 2009 and Jan.-Sep., 2010
Import Volume and Unit Price Trend of Heparin Products in China, 2008-Jan-Jul.2011
Destinations of China’s Heparin Product Imports, 2008- Jan-Jul.2011 
Import Origins of China Heparin Products, 2008- Jan-Jul.2011 
Heparin Sodium API Operating Revenue and YOY of Shenzhen Hepalink Pharmaceutical Co., Ltd., 2007- H1 2011 
Heparin Sodium API Revenue of Shenzhen Hepalink Pharmaceutical Co., Ltd by Product Grade, 2007- H1 2011
Gross Margin of Heparin API (by Product) of Shenzhen Hepalink Pharmaceutical Co., Ltd., H12007-2011
Operating Revenue of Shenzhen Hepalink Pharmaceutical Co., Ltd. by Region, 2007- H12011
Total Profit and YPY of Shenzhen Hepalink Pharmaceutical Co., Ltd., 2007- H12011 
Operating Revenue and Net Income of Changzhou Qianhong Bio-Pharma Co., Ltd., 2007- H1 2011
Operating Revenue (by Product) of Changzhou Qianhong Bio-Pharma Co., Ltd., 2008- H1 2011
Gross Margin (by Product) of Changzhou Qianhong Bio-Pharma Co., Ltd., 2009- H1 2011
Operating Revenue of Changzhou Qianhong Bio-Pharma Co., Ltd. by Region,2007- H1 2011
Top Five Clients of Heparin Sodium API of Changzhou Qianhong Bio-Pharma Co., Ltd, 2009-2010
R&D Input and Its Ratio to Operating Revenue of Changzhou Qianhong Bio-Pharma Co., Ltd, 2008-2010
Operating Revenue and Net Income of Tianjin Chase Sun Pharmaceutical Co., Ltd., 2007- H1 2011
Operating Revenue (by Product) of Tianjin Chase Sun Pharmaceutical Co., Ltd, 2009 - H1 2011
Gross Margin (by Product) of Tianjin Chase Sun Pharmaceutical Co., Ltd, 2008- H1 2011
Heparin Calcium Operating Revenue and YoY Growth of Tianjin Chase Sun Pharmaceutical Co., Ltd, 2007- H1 2011 
Operating Revenue of Tianjin Chase Sun Pharmaceutical Co., Ltd. by Region, 2008-2011H1 Competition and Distribution of Major Businesses of Tianjin Chase Sun Pharmaceutical Co., Ltd.
Operating Revenue and Net Income of Hebei Changshan Biochemical Pharmaceutical Co., Ltd, 2008-2010 
Operating Revenue (by Product) of Hebei Changshan Biochemical Pharmaceutical Co.,Ltd., 2008-2010
Gross Margin (by Product) of Hebei Changshan Biochemical Pharmaceutical Co.,Ltd., 2008-2010
Operating Revenue of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. by Region, 2008-2010
Sales of Top Five Customers of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. and Their Proportion to total Operating Revenue,2008-2010
R&D Input and Its Ratio to Operating Revenue of Hebei Changshan Biochemical Pharmaceutical Co.,Ltd.,2008-2010
Projects under R&D and Expected Target of Changshan Biochemical Pharmaceutical Co., Ltd.
Raising Project of Changshan Biochemical Pharmaceutical Co.,Ltd.
Heparin API Export of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd., 2009-2010 (Jan.-Sep. )
Operation of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd, 2008-2009 
Operation of Yantai Dongcheng Biochemicals Co., Ltd, 2008-2009 
Heparin API Export of Yantai Dongcheng Biochemicals Co., Ltd, 2009-2010 (Jan.-Sep. )
Operation of Wanbang Biopharmaceuticals, 2008-2009 

China Vacuum Blood Collection Industry Report, 2014-2017

The vacuum blood collection system consisting of vacuum blood collection tubes, disposable blood collection needles, tourniquets, etc transfers human venous blood to closed containers and makes it int...

China Pharmaceutical Excipients Industry Report, 2014-2017

Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are als...

China Recombinant Protein Drug Industry Report, 2014-2017

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein dru...

China Heparin Industry Report, 2014-2017

As the world's major heparin API producer and exporter, China boasts enormous raw materials, which provides a strong support for the production of China’s heparin products. In 2013, the live pigs rais...

Global and China Monoclonal Antibody Industry Report, 2014-2019

Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biot...

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

China Animal Vaccine Industry Report, 2013-2016

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...

China Contract Research Organization (CRO) Industry Report, 2013-2016

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share. ...

Global and China Biodegradable Plastics Industry Report, 2013-2016

Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...

Global and China Industrial Enzyme Industry Report, 2014-2016

In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...

China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...

China Lactic Acid and Derivative Industry Report, 2013

China’s lactic acid capacity and output continued to grow at the respective CAGR of 22.7% and 28.7% in 2007-2011. But limited by market demand, the annual output of most vendors was below their design...

China Human Vaccine Industry Report, 2012-2015

In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the...

China Blood Product Industry Report, 2012-2015

Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due...

China Animal Vaccine Industry Report, 2012-2015

In view of the frequent occurrence of animal epidemic diseases over the years, the Chinese government has increased investment in epidemic prevention and implemented compulsory immunization system. Be...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统